1

A variant by any name: quantifying annotation discordance across tools and clinical databases

Jennifer Yen[1], jennifer.yen@personalis.com

Sarah Garcia[1,2], stkgarcia@gmail.com

Aldrin Montana[1], aldrin.montana@personalis.com

Jason Harris[1], jason.harris@personalis.com

Steven Chervitz[1], schervitz@personalis.com

John West[1], john.west@personalis.com

Richard Chen[1], richard.chen@personalis.com

Deanna M. Church[1,2] , deanna.church@gmail.com

[1]Personalis, 1330 O'Brien Drive, Menlo Park, CA 94025

[2]10X Genomics, 7068 Koll Center Pkwy #401, Pleasanton, CA 94566

ABSTRACT

Background

Clinical genomic testing is dependent on the robust identification and reporting of

variant-level information in relation to disease. With the shift to high-throughput

sequencing, a major challenge for clinical diagnostics is the cross-identification of

variants called on their genomic position to resources that rely on transcript- or protein-

based descriptions.

Methods

We evaluated the accuracy of three tools (SnpEff, Variant Effect Predictor and Variation

Reporter) that generate transcript and protein-based variant nomenclature from genomic

coordinates according to guidelines by the Human Genome Variation Society (HGVS).

Our evaluation was based on comparisons to a manually curated list of 127 test variants

of various types drawn from data sources, each with HGVS-compliant transcript and

protein descriptors. We further evaluated the concordance between annotations

generated by Snpeff and Variant Effect Predictor with those in major germline and

cancer databases: ClinVar and COSMIC, respectively.

Results

We find that there is substantial discordance between the annotation tools and

databases in the description of insertion and/or deletions. Accuracy based on our ground

truth set was between 80-90% for coding and 50-70% for protein variants, numbers that

are not adequate for clinical reporting. Exact concordance for SNV syntax was over

99.5% between ClinVar and Variant Effect Predictor (VEP) and SnpEff, but less than

90% for non-SNV variants. For COSMIC, exact concordance for coding and protein

SNVs were between 65 and 88%, and less than 15% for insertions. Across the tools and

datasets, there was a wide range of equivalent expressions describing protein variants.

Conclusion

Our results reveal significant inconsistency in variant representation across tools and

databases. These results highlight the urgent need for the adoption and adherence to

uniform standards in variant annotation, with consistent reporting on the genomic

reference, to enable accurate and efficient data-driven clinical care.

KEYWORDS

HGVS, clinical genetic testing, genomics, annotation, sequencing, syntax, precision

medicine, variant

INTRODUCTION

High-throughput sequencing has transformed the landscape of clinical genetic testing.

This strategy, combined with the completion of massive public profiling datasets (ExAc

[1], 1000 Genomes [2]), has dramatically changed our approach towards cancer

treatment and the diagnosis of inherited disease. A major challenge in the analysis of

this throughput and volume of data is integrating variant level information from the

wealth of clinical and biological insight accumulated over decades of research,

particularly those from recent, large sequencing studies. Describing a variant's location

is a fundamental part of a clinical assessment, yet the practice remains difficult,

inconsistent and evolving.

Specifically, the clinical genomics community faces an enormous hurdle, which is

integrating data generated prior to the availability of a robust human reference assembly

with that generated using modern methods. Standards and guidelines for describing

variants at the genomic, transcript (coding) and protein level, provided by the Human

Genome Variation Society (HGVS) [3], were developed when testing was largely

transcript rather than genome-based. As laboratories shifted to high-throughput

sequencing, variant analysis transitioned to the genome level, confounding comparisons

with reports generated from previous transcript-based assays.

Reconciling variant coordinates from the transcript to the genome, and vice versa, is not

an unambiguous task. Requisite information about the genomic and transcript sequence

accessions, their versions, and the alignments used to relate the two sequences, are not

always reported in publications (Figure 1a-b). Alignment of cDNA to the genome remains

challenging and can result in substantially different exon structures depending on the

alignment approach (Figure 1a) [4,5]. In addition, variant reporting standards for VCF, a

format designed to store genomic variation, are different from those for HGVS, a format

that describes transcript and protein variants. In the context of nucleotide repeats, VCF

shifts left with respect to the genome, while HGVS shifts right with respect to the gene or

transcript (Figure 1c). Variants can therefore have very different locations depending on

their accession, version and alignment.

Even in relation to the same transcript, a variant can have multiple representations.

HGVS expressions can have long and short forms, preferred and non-preferred syntax,

and describe amino acids by their triple (e.g. Glu) or a single letter designation (e.g. E)

(Figure 1d). In a survey by Deans et al. (2016) [6], 20 laboratories reported the HGVS

syntax for a single variant in 14 different ways. An evaluation of over 140 molecular

pathology laboratories in Europe and the UK revealed substantial errors in reported

HGVS variant descriptions for the EGFR gene [7].

Currently there are many tools that automatically generate HGVS syntax, including

SnpEff [8], Variant Effect Predictor (VEP) [9], Annovar [10], Variation Reporter (VR) [11],

Mutalyzer [12] and packages developed by individual clinical laboratories such as Invitae

[5] and Counsyl [13]. While the performance of different genomic variant callers have

been well-studied [14,15], the accuracy and consistency of HGVS generation tools have

not yet been described.

Previous comparison of Annovar and VEP revealed substantial differences in annotation

based on choice of transcript [16]. This low concordance, combined with the increasing

demand for automated syntax generation, prompted our re-evaluation of the

performance of well-supported, open source tools. We considered only freely available

tools as they would have the largest reach. Additionally, we wished to focus on

annotation differences that can occur even when the same transcript is used. In this

paper, we compare the concordance of variant nomenclature generated by VEP [9],

SnpEff [8] and Variation Reporter, benchmarked by a curated 'truth' set and variant

annotations described in large public datasets for germline (ClinVar) and cancer

(COSMIC) variant descriptions. We find that while the tools SnpEff and Variant Effect

Predictor produce comparable results, there remains significant discordance in variant

annotation among tools, public resources, and literature.

METHODS

Datasets

We curated a test set of 127 variants to establish a ground-truth set with which we can

evaluate the accuracy of the tools. Fifty-one variants were selected from public

repositories: ClinVar, dbSNP, COSMIC, My Cancer Genome, Emory database and

Leiden (Additional file 1: Table S1). We added 76 synthetic variants to ensure

representation across variant types and genomic features. Genomic, coding and protein

nomenclature for all variants were generated using a combination of the Mutalyzer [17]

and Variation Viewer [18] webservice. Effect impact was determined based on the

protein syntax and sequence ontology (SO) [19].

We used the ClinVar GRCh37 VCF and annotations from the tab separated file

downloaded from the FTP site [20] (January 5th 2016 release). We used the rsid and

alternative allele to connect variants between the two files. We obtained genomic

coordinates from the COSMIC GRCh37 VCF and connected them with the transcript and

nomenclature in the CosmicCompleteExport.tsv file from the COSMIC website [21] (v75)

with the COSMID.

VCF normalization

We used vt-normalize [22] to left-justify all variants in each of the dataset VCFs used. A

breakdown of insertions and deletions (indels) for each dataset and the number

normalized is represented in Additional file 1: Table S2.

Tools used

We ran SnpEff (v4.1L) [8,23], VEP (v82) [9] and VR [11] on our ground truth set, and

subsequently only SnpEff and VEP on the ClinVar and COSMIC datasets. The Snpeff

database was built using the NCBI GRCh37 GFF corresponding to the NCBI annotation

'*Homo sapiens* 105'. The Snpeff database for Ensembl transcripts was built using the

GRCh37 Ensembl transcript GFF [24]. We ran VEP with the corresponding RefSeq or

Ensembl cache (v83). For all tools we used NCBI GRCh37p13 as the input reference

genome.

Assessment of syntax

To assess the performance of the variant annotation tools, we performed string match

comparisons between the output and the reference syntax (Figure 2). Annotations were

evaluated according to the HGVS guidelines [25, 26]. Variant annotations were labeled

as 'exact' matches when the HGVS string and the query annotation matched as-is. If the

string did not match perfectly, but could be transformed to the query string by applying

HGVS recommendations, the tool's annotation was labeled 'equivalent'. For this study,

both 'exact' and 'equivalent' annotations are regarded as correct. The code and module

for performing the syntax assessment will be distributed on GitHub.

RESULTS

Comparisons to a ground truth test set

In order to assess the performance of different variant annotation tools against a ground

truth, we used a contrived test set of 127 manually curated variants (Figure 3a)

comprised of 52 previously reported variants in the literature or databases, and an

additional 76 synthetic variants targeting a spectrum of variants (Additional file 1:

Table S3). All annotations were reviewed manually using a combination of the

Mutalyzer and Variation Viewer web services. This structured test set would allow us

to deeply evaluate variants across different classes, effects, and genomic features.

Using the analysis flowchart summarized in Figure 4, we compared the annotations

generated by VR, VEP [9] and SnpEff [8] to the ground-truth test set (Additional File 1:

Table S4). VEP and SnpEff accept VCF as input files; at the time of analysis, the VR

API was limited in its functionality in processing large VCF files. Input HGVS

expressions were also required for Mutalyzer, but we did not assess this tool because

it was used to construct the ground truth set. We compared only annotations made on

the same RefSeq transcript version. Although the input transcript alignments for

SnpEff and VEP were identical, the tools produced a different number of transcripts

and annotations. For example, we could not extract the relevant transcript for 4

variants in the SnpEff output and 5 from the VEP output, in addition to 5 variants

absent from both tools. The importance of transcript collection was more pronounced

for VR, which uses its own in-house alignments. As a result, 18% of the test variants

could not be assessed by VR because NCBI carries only the most up-to-date

transcripts. VR also frequently yielded multiple annotations for a single variant and

transcript. In these cases, we chose the first variant in the output to evaluate in this test.

In total, only 121 out of the 127 variants were annotated on the relevant transcript for

any of the three tools.

A major challenge in comparing nomenclature between tools was evaluating the

equivalency of the many HGVS expressions for a given variant. Protein variant syntax

was far more variable than coding variant syntax: between 14-20% of protein

annotations were described with equivalent nomenclature across the three tools,

compared to only 2.5% to 3.0% of coding syntax (Figure 4c-d). Each tool had distinct

frameshift and synonymous annotations; frameshift has both long and short form

alternatives, while synonymous variants can be described in several ways; e.g. 'p.(=)',

'p.=', 'p.Thre258=', 'p.Thr258Thr' (PTV012, Additional file 1: Table S5). Exact

concordance in annotation between SnpEff and VEP was higher at the coding level

(77.6% of variants) than at the protein level (68.8.1%) (Figure 4b, right panel). Less

agreement was observed between Variation Reporter and either VEP or SnpEff:

approximately 50% with either tool for coding and protein syntax.

For variants in our ground-truth set, SnpEff and VEP exhibited comparable accuracy

and precision. At the coding level, SnpEff, VEP and VR annotated between 80% and

85% of substitutions correctly (out of 65 and 68), compared to 100% of substitutions

for VR (out of 55). For deletions and insertions, VR performed poorly largely due to

systematic errors in reporting. VR incorrectly described all but two deletions as indels.

The remaining two annotations diverged from HGVS guidelines by omitting the 'del'

designation altogether (e.g. c.2199-1301GA>A) (PTV062, PTV067, Additional file 1:

Table S5). Duplications were also annotated as indels, but with technically equivalent

(and redundant) nomenclature (c.1961dupG as c.1960delCinsCG). Such VR errors at

the coding level led to inaccurate protein syntax for 18 variants.

We tested the ability of the tools to discriminate between the genomic reference and

RefSeq transcript sequences, both of which are independently curated by the NCBI

[27]. Since RefSeq transcripts typically receive a high level of manual review, conflicts

between the RefSeq and genomic sequence often reveal an error in the latter. For this

reason, we included nine test instances of RefSeq-Genomic differences in our ground

truth set. Strikingly, none of the nine test examples of RefSeq-Genomic differences

were identified by either VEP or SnpEff (Additional file 1: Table S5), and were

erroneously reported as missense or deletion variants. While VR correctly identified 7

out of 9 RefSeq Genomic differences (the remaining two variants were not

annotated), it mistakenly called differences for an additional 22 variants, indicating a

poor precision for recognizing true differences. HGVS expressions should always

reflect the base on the relevant genomic or transcript sequence to avoid asserting

variants at positions where there is no change.

Both SnpEff and VEP correctly annotated the phased dinucleotide substitutions,

which are variants present in consecutive bases, also known as multinucleotide

variants (MNV) (Additional file 1: Table S6). Dinucleotide substitutions are highly

prevalent in cancers associated with clear mutagen exposures such as melanoma, lung

adenoma and lung squamous cell carcinoma [28]. Similarly, treatment by the

chemotherapeutic agents cisplatin and meclorethamine have also been shown to cause

dinucleotide substitutions at appreciable rates [28]. VR incorrectly annotated the phased

dinucleotide substitutions as frameshift variants (PTV044, PTV068). We found that

MNVs must be phased in the VCF, as the tools annotated adjacent but independent

substitutions in the VCF separately instead of as a pair. For example, two BRAF

variants (PTV045, PTV046) were incorrectly annotated as p.V600E and p.V600M, when

the combined result would be p.V600K. These results indicate that for cancers with a

high mutation load, prior phasing for dinucleotide pairs will be especially crucial to

circumvent potential clinical oversights [29].

To complement the analysis of protein and coding annotations, we also assessed the

variant effects predicted by the tools. Predicted effect is commonly used for

evaluating pathogenicity during variant interpretation [30]. In instances where a

variant could be associated with two functional consequences (for example, as

intronic but also at a slice acceptor site), the annotation was considered to be correct

if one association was described. Overall, the accuracy of effect prediction correlated

highly with that of protein annotation (Additional file 1: Figure S1) even if they are

calculated independently [8]). Compared to coding and protein syntax, efforts among

tools to converge on a standardized set of variant effect annotations were far more

evident (Additional file 2: Figure S1).

Comparison with the ClinVar dataset

Having established baseline accuracy for automated syntax generation, we sought to

assess the syntax concordance of these tools with those in public datasets. We

started with ClinVar [31], a large public archive of variant and disease relationships

that is widely used for evaluating Mendelian disease. Of the 106,110 small variants in

the ClinVar VCF, the vast majority are SNVs (84%); the rest comprise a smaller

number of deletions (10%), duplications (3.3%), insertions (1%) and indels (1%)

(Figure 3b). We evaluated the performance of VEP and SnpEff on the ClinVar dataset

(Additional file 3); because of the limited functionality and long running time of the VR

tool, we did not include it in subsequent annotation assessments (Additional file 1:

Table S7).

Approximately 10% of transcripts in the ClinVar dataset had different versions from

those in our input transcript alignment file, which was used to build resources for both

VEP and SnpEff (Figure 5a). Approximately 1.8% of ClinVar transcript accessions

were not represented in the alignment input at all. Because of these discrepancies in

transcript accession and versions, we could not assess the SnpEff or VEP

annotations for 7 and 7.5% of ClinVar variants, again underscoring the importance of

the input transcript set.

280 Overall concordance for both SnpEff and VEP was remarkably high, which can be

281 attributed to the large proportion of SNVs (Figure 5b). At the coding level, both SnpEff

282 and VEP yielded nearly perfect concordance for SNVs, matching the exact ClinVar

283 nomenclature for over 99.9% of the SNVs (Figure 5a, Additional file 2: Figure S2b). In

284 rare instances of error, SnpEff and VEP were typically incorrect by one base

285 (Additional file 1: Table S8). Exact concordance was lowest for variants annotated as

286 insertions in ClinVar (approximately 75-80% for both tools), largely due to their correct

287 assertion as duplications by VEP and SnpEff. In contrast, concordance was slightly

288 higher for deletions and indels (between 86 and 88%). There were 25 instances in

289 which neither tool could have predicted correct coding HGVS syntax without prior

290 reports of the splicing product. A single nucleotide change at a splice site in the AGA

291 gene NC_000004.11:g.178354367C>A (NM_000027.3:c.940+1G>T) results in the

292 skipping of exon 8 and a final syntax of c.807_940del134 (Additional file 1: Table S9). In

293 five of these cases, this type of error also resulted in the incorrect protein syntax.

295 As with the ground truth test set, we observed greater variation in protein syntax

296 (Table 1). This was mostly evident for deletions, duplications, and insertions, where

297 between 16 to 78% of annotations were reported correctly but with alternative

298 nomenclature (Additional file 2: Figure S2b). Overall concordance was again high for

299 SNVs (99%), with 75% and 83% exact nomenclature for SnpEff and VEP. However,

300 neither VEP nor SnpEff performed as well on deletions, duplications and insertions

301 (between 76.3% and 94.4% overall concordance). For non-SNV variant types, our

302 results show that between 60-70% of annotations output by these tools do not match

303 the ClinVar HGVS, and between 5-20% of these annotations are completely

304 discordant. Dinucleotide substitutions, which ClinVar reports as indels, were

annotated as independent substitutions for both SnpEff and VEP (Additional file 1:

Table S6). In a few cases at the boundaries between coding and non-coding regions,

VEP and ClinVar yielded no output while SnpEff reported the ambiguity as

'p.Thr662_Glu663delins???'. Even for substitutions, there were instances where all three

tools yielded distinct nomenclature for the same variant. For

NM_001126128.1:c.163delA, ClinVar, SnpEff and VEP output p.Ile55Terfs, p.Ile55fs,

and p.Ile55Ter respectively. The correct HGVS syntax for this variant is p.Ile55Ter.

Interestingly, agreement between SnpEff and VEP sometimes revealed errors or

inconsistencies in the ClinVar output. For example, for rs34618570, the TTN variant

NM_133378.4:c.10361-2293A>T is purported to be a missense variant (p.Ile3877Phe),

when the variant is intronic for that transcript. For rs398123611 (Additional file 1: Table

S8), ClinVar recognizes NM_133378.4:c.1138_1140dupGGC as a duplication in the

coding syntax but annotates the protein as an insertion (p.Gly380_Ala381insGly). At

least 626 variants in the ClinVar dataset were incorrectly annotated as both nonsense

and frameshift (p.Glu307Terfs), when the output should simply be nonsense. Together,

these results demonstrate that while there is near perfect consensus between the HGVS

tools and ClinVar annotations for SNVs, the uniformity and correctness for other variant

types, which are often of the most clinically relevant (e.g. frameshifts), still needs

improvement.

Comparison with the COSMIC dataset

Clinical cancer care is dependent on identifying relationships between tumor variants

and relevant information about their prognostic and therapeutic significance. We

investigated the consistency between annotation output by SnpEff and VEP with

COSMIC, currently the largest public resource of somatic mutations in human cancer

[32] that is also widely used by clinical laboratories. Again, we did not include VR in

our assessment because of its limited functionality and long running time. Because

COSMIC annotates variants in relation to Ensembl instead of NCBI RefSeq transcript

accessions, we built a second, separate database to run VEP and SnpEff according to

Ensembl transcript alignments.

We queried a total of 3,075,504 coding COSMIC variants. Following normalization and

de-duplication of the COSMIC VCF, there remained a set of 2,215,076 variants (Figure

3). Approximately 142,134 variants were insertions, deletions or indels, 19% of which

required left justification (Additional file 1: Table S2). We compared syntax

representations (Figure 5c, Additional file 4). Both SnpEff and VEP generated

annotations for approximately 90% of the COSMIC dataset. Because the cancer field

employs the convention of abbreviating amino acids to a single letter while the

annotation tools, and HGVS, all use the three-letter convention, we converted the

COSMIC annotations to three-letter amino acids to facilitate annotation comparison.

At the coding level, VEP recapitulated the exact syntax as COSMIC for 85.9% of the

total variants, compared to 76.8% of variants by SnpEff, with less than 1% of

equivalent syntax for both tools (Figure 5b). However, the majority of the COSMIC

dataset are SNVs (95%); for variant types other than SNVs, neither VEP nor SnpEff

achieved comparable concordance (Additional File 2: Figure S2b). Notable

differences in annotations include COSMIC's reporting of all duplications as

insertions, resulting in nearly complete discordance for variants of this type. We did

not assert the equivalency of multi-base insertions with duplications due to the

involvement of verifying duplicated bases in the reference transcript. As a result, none

of the indel annotations were exact string matches. Additionally, in complete

departure from current HGVS standard, COSMIC reports indels as block substitutions

(c.569_570TC>AT vs c.569_570delTCinsAT, Table 1), which we assessed as

'equivalent'. This format could be attributed to the historical representation of

dinucleotide variants [33], which remains popular despite the adoption of the HGVS

standard by most clinical resources (e.g. My Cancer Genome). By failing to

consistently right justify insertion and deletion positions, the concordance between

tools and COSMIC nomenclature for deletions was less than 50% (Additional file 1:

Table S10).

For protein variants, SnpEff reproduced the exact protein syntax for 75.8% of

COSMIC variants compared to 58.4% by VEP (Figure 5b). A large fraction of VEP

discordance could be attributed to VEP's annotation of all frameshifting indels as

nonsense variants (Additional file 1: Table S10, COSM1476431). Further, over 90% of

VEP alternative protein expressions were due to discrepant reporting of synonymous

variants as p.= compared to p.Gly35Gly by both COSMIC and SnpEff (Table 1).

Similar to coding deletions, nuances in nomenclature revealed distinct expressions of

frameshifts for COSMIC, VEP and SnpEff.

For the majority of discordant annotations, the agreement between SnpEff and VEP

syntax suggest that the COSMIC syntax is incorrect. To verify the HGVS nomenclature

of these variants, we mapped the Ensembl transcript to its approximate corresponding

RefSeq accession through its consensus coding sequence (CCDS), since a number of

tools, including Mutalyzer, do not support Ensembl identifiers. A mutation in *TP53* at

position chr17:7578525 (COSM1683507) is annotated in COSMIC as c.404_405insC.

Because of a sequence of 4 C's at this position, the standardized left shifted VCF

position should be at chr17:7578523 and right-shifted HGVS syntax as c.405_406insC,

or c.405dupC. In another example, a HER2 insertion variant is described in My Cancer

Genome as c.2339_2340ins (with no insertion bases or transcript as reference) and

G778_P780dup. The correct coding syntax by both SnpEff and VEP is c.2331_2339dup

while the correct protein syntax (output only by VEP) is p.Gly778_Pro780dup. COSMIC

annotated neither the coding or protein syntax correctly (Table 1). Based on the

agreement of VEP and SnpEff alone, our results suggest that at least 2.7% of COSMIC

variant annotations are incorrect (Table 1). This is not surprising given its recent

transition from a research repository to a major clinical resource, although efforts to

comply with genomic and HGVS standards are apparently underway.

Clinical impact of discordant variant annotation

Ultimately, we are concerned about the concordance of positional and syntax

expressions because of its impact on clinical interpretation. To illustrate this point, we

describe a frameshift variant in the *PROK2* gene, which was differentially classified as

an exercise by two curators in our laboratory - one classifying as likely pathogenic

and the other as pathogenic for Kallman syndrome. The difference in classification

stemmed from the use of different syntax in constructing the string-based search. The

variant was described as 'NM_001126128.1:c.297dupT (p.Gly100Trpfs*22)'. Because

of alternative transcripts and HGVS representations, this variant could be searched by

multiple expressions (Additional file 1: Figure S3a). In one route, searching 'PROK2

c.297_298insT' or 'PROK2 c.234_235insT' immediately retrieved the relevant

literature to classify this variant. However, searching 'PROK2 *297_298ins*', 'PROK2

234_235ins', or the correct HGVS syntax 'c.297dup' or 'c.234dup' did not return any

relevant results (Additional file 1: Figures S2b). Searching for 'PROK2 G100fsX121',

'PROK2 c.297_298insT' or 'PROK2 c.234_235insT' identifies a paper by Abreu et al.

[34], which leads to a thread of reports that supports a final variant classification of

'pathogenic' (Additional file 1: Figure S3b-c). Because of these multiple variant

representations, identifying relevant information can entail navigating a complex matrix

of HGVS expressions and web results.

As another example of the importance of accurate HGVS nomenclature for clinical

care, a variant in a patient's melanoma sample was annotated in our pipeline as

'NM_004333.4:c.1799T>A (p.V600E)'. During visual review we found that the variant

was part of a dinucleotide pair, with a combined syntax of c.1799_1800delTGinsAT

and protein syntax of p.V600D. Although p.V600D is sensitive to BRAF inhibitors, this

variant is not as well-studied and characterized with respect to drug response and

efficacy compared p.V600E. Further, while V600E confers sensitivity to MEK

inhibition, the sensitivity of p.V600D to MEK remains unclear.

DISCUSSION

We have described some of the remaining challenges of moving clinical sequencing

into a high-throughput environment. Consistent with findings by McCarthy et al. [16],

we find that the transcript collection has a significant impact on the yield of relevant

variant annotations. Our examination of automated syntax from HGVS tools and the

ClinVar or ground truth datasets reveal that approximately 10% of variants could not

be assessed due to discordant transcript accessions or versions. The fact that ClinVar

and COSMIC, the largest public repositories of germline and somatic data

respectively, do not share the same collection of transcript accessions reflects the

degree of harmonization and the need for a universal store of transcript to genome

alignments.

Importantly, although variant calling is performed almost exclusively on genomic data,

variants are still being primarily referenced with respect to the transcript. Recent

publications continue to describe variants according to their protein and/or coding

syntax [35-37], sometimes even without the transcript identifier [38,39]. In a survey by

the American Society of Molecular Pathologists, 50% of clinical cancer labs report

variants exclusively by coding and protein HGVS nomenclature but without

accompanying genomic coordinates. The same survey also found that 70% of clinical

cancer labs use as a resource MyCancerGenome.org, which references variants by

their popular single-letter amino acid or coding-level convention, again, without

transcript or genomic coordinates. As our analyses show, transforming genomic

positions to transcript loci is challenging and prone to error; ambiguity in

representation is best avoided by always referencing variants by their genomic

position and assembly version. For this reason, HGVS recommends reporting clinical

variants by their Locus Reference Genomic sequence (LRG), a system designed for

clinically relevant variants that is based on un-versioned and stabled accession

sequences [26,40].

Despite the precision achieved with generating syntax for SNVs, the positions of

insertions and/or deletions remain stubbornly difficult to annotate, regardless of the

VCF or HGVS genomic standard. The presence of duplicates in nearly one-fifth of the

COSMIC VCF highlights the importance of using tools for normalization to reconcile

the multiple possible positions to represent a single variant. At the level of HGVS, we

found that none of the non-SNV variant types were annotated with near 100%

accuracy or compliance with HGVS conventions for any of the tools or databases that

we queried. Given the rigorous reporting requirements of a clinical genetics lab, this is

concerning, and suggests that it remains critical to manually review the syntax when

reporting non-SNVs.

Our analyses further provide a glimpse into the diverse matrix of possible HGVS

representations for a given variant - a disturbing concept for attempts to mine and

exploit existing resources through string-based search. Internal efforts can be made to

standardize HGVS syntax within knowledge-bases and clinical enterprises; variants

can be transformed into a standard, minimal expression to enable a uniform query

across curated databases [41]. However, while this is useful for a limited set of data, it

is impractical for mining beyond internally curated information. The alternative is

exhaustive but impractical, requiring the search for every permutation of an HGVS

expression for a particular variant. A thoughtful discussion should be made about

asserting HGVS guidelines as rules to enforce a strict convergence across

laboratories, resources, and literature.

By design, the HGVS annotation system was not intended for mining large bodies of

genomic information, while approximations of syntax are not acceptable because of

their impact on clinical care. A means of clinical intervention in oncology is to directly

connect clinically actionable variants in patient tumor samples with relevant therapeutic

strategies, such as approved drugs or eligibility for clinical trials. In the ACMG guidelines

for the classification of germline variants, at least five categories of evidence require

interrogating variants from previous reports in reliable databases or the published

literature [30]. Already, studies have shown that there remains substantial heterogeneity

in the interpretation of genomic variants by clinical laboratories [6,7,42]. Imprecise

nomenclature can lead to variant misclassification and consequent misdiagnosis [29].

The applications of genomics in clinical care will require concerted efforts to converge on

standardized reporting mechanisms to enable data sharing and integration across

diverse datasets and resources. Reporting on the same genomic reference, according to

uniform variant syntax, will be one crucial step towards the achieving this aim and the

ultimate goal of precision medicine.

DECLARATIONS

List of abbreviations

HGVS, Human Genome Variation Society; VEP, Variation Effect Predictor; VR, Variation

Reporter; VCF, Variant Call Format

Competing Interests

JY, SG, AM, JH, SC, JW, RC, DMC were full time employees of Personalis at the time of

this study.

Authors' contributions

JY designed the study, performed the bioinformatics and data analysis, interpreted

results and wrote the manuscript. DMC conceived the idea and guided the study design,

results interpretation and manuscript preparation. SG contributed to the data analysis,

study design and results interpretation. AM and SC contributed to the bioinformatics

analysis. Both AM and JH provided guidance for the bioinformatics analysis. All authors

read and approved the final manuscript.

Acknowledgements

We thank Dariya Glazer and Joshua Anderson for their contributions in classifying the

PROK2 variant; Christian Haudenschild for his guidance on the dataset submission and

Massimo Morra for his keen eye in HGVS nomenclature.

ADDITIONAL FILES

Additional file 1

Table S1. Ground Truth Set Variants

Table S2. Variants Normalized by Dataset

Table S3. Ground Truth Set Contents by Features

Table S4. Ground Truth Set Comparison Results. Exact matches between the

reference annotation in COSMIC and annotations provided by Snpeff and VEP

are noted as "yes", equivalent matches as "yes_m" ("yes modified") and not

equivalent annotations as "no".

Table S5. Example Nomenclature Discrepancies Ground Truth Set Variants

Table S6. Annotation of dinucleotide substitutions

Table S7. Tools Run Time

Table S8. Example Nomenclature Discrepancies from the ClinVar Dataset

Table S9. Examples of genomic SNVs resulting in deletions at the transcript level

Table S10. Example Nomenclature Discrepancies from the COSMIC Dataset

Additional file 2.

Figure S1. Comparison of effect annotation between tools and the HGVS

test set.

a) Concordance in effect nomenclature between the HGVS test set and SnpEff

and VEP by variant type.

Figure S2. Concordance in variant syntax by variant type between tools and a)

ClinVar or b) COSMIC datasets at the coding (upper panel) and protein (lower

panel) level. Bars represent fraction of exact (blue) and equivalent (orange)

matches. All duplications were marked as insertions in COSMIC.

Figure S3. Impact of HGVS nomenclature on clinical interpretation

a) Transcripts and nomenclature associated with variant (chr3:g.71821968dupA).

b) PubMed and Google results from search strings.

c) From a single search string to evidence and classification.

Additional file 3. ClinVar Comparison Results. Exact matches between the reference

annotation in COSMIC and annotations provided by Snpeff and VEP are noted as "yes",

equivalent matches as "yes_m" ("yes modified") and not equivalent annotations as "no".

Additional file 4. COSMIC Comparison Results. . Exact matches between the reference

annotation in COSMIC and annotations provided by Snpeff and VEP are noted as "yes",

equivalent matches as "yes_m" ("yes modified") and not equivalent annotations as "no".

REFERENCES

1. Lek M. ExAC_Main_Submission_151029. 2015 Oct pp. 1–26.

2. Altshuler DL, Abecasis GR, Chakravarti A, La Vega De FM, Donnelly P, Gibbs RA, et al. A map of human genome variation from population-scale sequencing. Nature. 2010;467:1061–73.

3. Dunnen den JT, Antonarakis SE. Mutation nomenclature extensions and suggestions to describe complex mutations: a discussion. Hum. Mutat. 2000;15:7–12.

4. Kapustin Y, Souvorov A, Tatusova T, Lipman D. Splign: algorithms for computing spliced alignments with identification of paralogs. Biol Direct. 2008;3:20–13.

5. Hart RK, Rico R, Hare E, Garcia J, Westbrook J, Fusaro VA. A Python package for parsing, validating, mapping and formatting sequence variants using HGVS nomenclature. Bioinformatics. 2015;31:268–70.

6. Deans Z, Fairley JA, Dunnen den JT, Clark C. HGVS Nomenclature in Practice: An Example from the United Kingdom National External Quality Assessment Scheme. Hum. Mutat. 2016.

7. Tack V, Deans ZC, Wolstenholme N, Patton S, Dequeker EMC. What's in a Name? A Coordinated Approach toward the Correct Use of a Uniform Nomenclature to Improve Patient Reports and Databases. Human Mutation. 2016;37:570–5.

8. Cingolani P, Platts A, Wang LL, Coon M, Nguyen T, Wang L, et al. A program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEff: SNPs in the genome of Drosophila melanogaster strain w1118; iso-2; iso-3. Fly (Austin). 2012;6:80–92.

9. McLaren W, Pritchard B, Rios D, Chen Y, Flicek P, Cunningham F. Deriving the consequences of genomic variants with the Ensembl API and SNP Effect Predictor. Bioinformatics. 2010;26:2069–70.

10. Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Research. 2010;38:e164–4.

11. Variation Reporter [Internet]. http://www.ncbi.nlm.nih.gov/variation/tools/reporter. [cited 2016 May 16]. Available from: http://www.hgvs.org/mutnomen/

12. Wildeman M, van Ophuizen E, Dunnen den JT, Taschner PEM. Improving sequence variant descriptions in mutation databases and literature using the Mutalyzer sequence variation nomenclature checker. Hum. Mutat. 2008;29:6–13.

13. Counsyl HGVS variant name parsing and generation [Internet]. [cited 2016 May 16]. Available from: https://github.com/counsyl/hgvs

14. Hwang S, Kim E, Lee I, Marcotte EM. Systematic comparison of variant calling pipelines using gold standard personal exome variants. Scientific Reports. The Author(s) SN ; 2015;5:17875.

15. Cornish A, Guda C. A Comparison of Variant Calling Pipelines Using Genome in a
Bottle as a Reference. BioMed Research International. 2015;2015:1–11.

16. McCarthy DJ, Humburg P, Kanapin A, Rivas MA, Gaulton K, Cazier J-B, et al.
Choice of transcripts and software has a large effect on variant annotation. Genome
Med. 2014;6:26.

17. Taschner PEM, Dunnen den JT. Describing structural changes by extending HGVS
sequence variation nomenclature. Lindblom A, Robinson PN, editors. Human Mutation
[Internet]. 2011;32:507–11. Available from: https://mutalyzer.nl/

18. Variation Viewer [Internet]. [cited 2016 May 16]. Available from:
http://www.ncbi.nlm.nih.gov/variation/view/

19. Eilbeck K, Lewis SE, Mungall CJ, Yandell M, Stein L, Durbin R, et al. The Sequence
Ontology: a tool for the unification of genome annotations. Genome Biology.
2005;6:R44–12.

20. ClinVar FTP Site [Internet]. [cited 2016 May 16]. Available from:
ftp://ftp.ncbi.nlm.nih.gov/pub/clinvar/

21. COSMIC [Internet]. [cited 2016 May 16]. Available from:
http://cancer.sanger.ac.uk/cosmic/download)

22. Tan A, Abecasis GR, Kang HM. Unified representation of genetic variants.
Bioinformatics. 2015;31:2202–4.

23. SnpEff [Internet]. [cited 2016 May 16]. Available from: http://snpeff.sourceforge.net/

24. Ensembl FTP Fownload [Internet]. [cited 2016 May 16]. Available from:
http://www.ensembl.org/info/data/ftp/index.html

25. HGVS Website [Internet]. [cited 2016 May 16]. Available from:
http://www.hgvs.org/mutnomen

26. Dunnen den JT, Dalgleish R, Maglott DR, Hart RK, Greenblatt MS, McGowan-
Jordan J, et al. HGVS Recommendations for the Description of Sequence Variants:
2016 Update. Human Mutation. 2016;:n/a–n/a.

27. Pruitt KD, Brown GR, Hiatt SM, Thibaud-Nissen F, Astashyn A, Ermolaeva O, et al.
RefSeq: an update on mammalian reference sequences. Nucleic Acids Research.
2014;42:D756–63.

28. Meier B, Cooke SL, Weiss J, Bailly AP, Alexandrov LB, Marshall J, et al. C. elegans
whole-genome sequencing reveals mutational signatures related to carcinogens and
DNA repair deficiency. Genome Research. Cold Spring Harbor Lab; 2014;24:1624–36.

29. Varga E, Chao EC, Yeager ND. The importance of proper bioinformatics analysis
and clinical interpretation of tumor genomic profiling: a case study of undifferentiated
sarcoma and a constitutional pathogenic BRCA2 mutation and an MLH1 variant of
uncertain significance. Familial Cancer. Springer Netherlands; 2015;:1–5.

30. Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and
guidelines for the interpretation of sequence variants: a joint consensus recommendation
of the American College of Medical Genetics and Genomics and the Association for
Molecular Pathology. Genet Med. 2015;17:405–23.

31. Landrum MJ, Lee JM, Benson M, Brown G, Chao C, Chitipiralla S, et al. ClinVar:
public archive of interpretations of clinically relevant variants. Nucleic Acids Research.
Oxford University Press; 2016;44:D862–8.

32. Forbes SA, Beare D, Gunasekaran P, Leung K, Bindal N, Boutselakis H, et al.
COSMIC: exploring the world's knowledge of somatic mutations in human cancer.
Nucleic Acids Research. 2015;43:D805–11.

33. Pleasance ED, Cheetham RK, Stephens PJ, McBride DJ, Humphray SJ, Greenman
CD, et al. A comprehensive catalogue of somatic mutations from a human cancer
genome. Nature. Macmillan Publishers Limited. All rights reserved; 2009;463:191–6.

34. Abreu AP, Trarbach EB, de Castro M, Frade Costa EM, Versiani B, Matias Baptista
MT, et al. Loss-of-function mutations in the genes encoding prokineticin-2 or prokineticin
receptor-2 cause autosomal recessive Kallmann syndrome. J Clin Endocrinol Metab.
2008;93:4113–8.

35. Zhu X, Petrovski S, Xie P, Ruzzo EK, Lu Y-F, McSweeney KM, et al. Whole-exome
sequencing in undiagnosed genetic diseases: interpreting 119 trios. Genet Med.
2015;17:774–81.

36. Helbig KL, Farwell Hagman KD, Shinde DN, Mroske C, Powis Z, Li S, et al.
Diagnostic exome sequencing provides a molecular diagnosis for a significant proportion
of patients with epilepsy. Genet Med. 2016;:1–8.

37. Yang Y, Muzny DM, Reid JG, Bainbridge MN, Willis A, Ward PA, et al. Clinical
Whole-Exome Sequencing for the Diagnosis of Mendelian Disorders. New England
Journal of Medicine. 2013;369:1502–11.

38. Soden SE, Saunders CJ, Willig LK, Farrow EG, Smith LD, Petrikin JE, et al.
Effectiveness of exome and genome sequencing guided by acuity of illness for diagnosis
of neurodevelopmental disorders. Sci Transl Med. 2014;6:265ra168.

39. Pansuriya TC, van Eijk R, d'Adamo P, van Ruler MAJH, Kuijjer ML, Oosting J, et al.
Somatic mosaic IDH1 and IDH2 mutations are associated with enchondroma and
spindle cell hemangioma in Ollier disease and Maffucci syndrome. Nat Genet.
2011;43:1256–61.

40. MacArthur JAL, Morales J, Tully RE, Astashyn A, Gil L, Bruford EA, et al. Locus
Reference Genomic: reference sequences for the reporting of clinically relevant
sequence variants. Nucleic Acids Research. 2014;42:D873–8.

41. Patterson SE, Liu R, Statz CM, Durkin D, Lakshminarayana A, Mockus SM. The
clinical trial landscape in oncology and connectivity of somatic mutational profiles to
targeted therapies. Human Genomics. Human Genomics; 2016;:1–13.

42. Pepin MG, Murray ML, Bailey S, Leistritz-Kessler D, Schwarze U, Byers PH. The
challenge of comprehensive and consistent sequence variant interpretation between
clinical laboratories. Genet Med. 2015;18:20–4.

FIGURES

a. Reproducing transcript structure with the allignment approach

b. Identifying the relevant transcript accession and version

c. Left or right justification of the sequence variant

		Pos.	Pos.
		VCF (left shift)	HGVS (right shift)
Ref	ACCTTTTTGTCTG		
Alt	ACCTTTTTTGTCTG	4	9

d. Transcript annotation and translation to protein

NM_003119.3:c.90dupT → NP_003110.1: p.Pro31Serfs*43
NM_003119.3:c.91dupT → NP_003110.1: p.Gly32Argfs*42

e. Representing the variant with a preferred expression.

NM_003119.3: c.90dupT   NP_003110.1: p.Pro31Serfs*43
                c.89_90insT   p.Pro31fs
                                               p.Pro31Terfs

Figure 1. Factors affecting HGVS syntax generation.

a) Transcript alignment approach can impact the transcript exon structure. Alignment of cDNA
sequence by Splign and BLAT to the genome results in a 10kb difference in an exon positioning
in the CARD9 gene (green arrow).

b) Transcript accession can impact the variant association and HGVS syntax. Here, the identified
GNAS variant is outside the clinically relevant transcript. Small changes in versions may also
impact the coding sequence.

c) In the context of nucleotide repeats, variant justification can affect the variant's position.

d) Transcript annotation directly impacts its translation to a protein expression. Incorrect transcript
annotation can lead to incorrect protein syntax.

e) Representing the variant in a particular expression. There are different ways of expressing the
same coding or protein variant.

Figure 2. Methodology of HGVS syntax comparison.

To compare two HGVS expressions in our dataset, we applied the following assessments.

a) The query transcript must match the reference transcript. If the accession or version

does not match, the variant is not assessed.

b) If the syntax for both expressions correspond as-is, the match is 'exact'.

c) If the syntax for both expressions are equivalent, the match is 'equivalent', If the syntax is not
an alternative expression of the other HGVS variant, the match is 'incorrect'.

Figure 3. Datasets by composition.

a) Number of variants evaluated in the Ground Truth, ClinVar and COSMIC dataset. Note that the number of variants assessed may be less than the number of variants in the input set.

b) Distribution of variant types for each dataset. Duplications are included under insertions.

Figure 4. Summary of ground truth set HGVS syntax assessment.

a) Fraction of unique transcript accessions and versions in the ground truth set that were available to the tools SnpEff (snpeff), VEP (vep), and Variation Reporter (vr). If a transcript was not accessible to the tool, the variant could not be annotated with respect to that transcript.

b) Exact concordance of HGVS syntax at the coding (left) and protein (right) level among the tools.

c) Accuracy of annotation across variants (n=121) described as exact (blue) and equivalent
(orange). Fraction shown is with respect to number of annotations on the relevant transcript on
the test set.

d) Accuracy of annotation for each variant type across the tools. Variant types evaluated were:
deletions (del), indels (delins), duplications (dup), insertions (ins) and single nucleotide variatnts
(SNVs).

a. ClinVar transcript accessions and versions available to tools

b. ClinVar concordance across all variants

c. COSMIC concordance across all variants

Figure 5. ClinVar and COSMIC HGVS syntax assessment.

a) ClinVar transcript accessions and versions available to tools. Transcripts available to tools that
matched the ClinVar reference transcript are marked in blue; transcripts that were different
versions from the ClinVar transcript are marked in orange. Only unique transcripts were
considered.

b) Overall concordance in variant syntax across all variants between tools and ClinVar at the
coding (upper panel) and protein (lower panel) level. Bars represent fraction of exact (blue) and
equivalent (orange) matches.

c) Overall concordance in variant syntax across all variants between tools and COSMIC at the
coding (upper panel) and protein (lower panel) level. Bars represent fraction of exact (blue) and
equivalent (orange) matches. All duplications were considered insertions in COSMIC.

Table 1. Exemplar variants demonstrating nomenclature discrepancies

Coding HGVS

variant type	ClinVar	COSMIC	SnpEff	Vep	VR	Reference ID
insertion	-	c.2262_2263ins14	-	c.2262_2263insGGCATCTCAGCATC	-	COSM5254274
duplication	-	c.422_423insA	c.428dupA	c.428dupA	-	COSM4719972
duplication	c.567_568dup	-	c.567_568dupTT	c.567_568dupTT	-	rs137854332
indel	-	c.3141_3142GA>TT	c.3141_3142delGAinsTT	c.3141_3142delGAinsTT	-	COSM4387531
indel	c.68-5_68-3delinsTT	-	c.68-5_68-3delCTCinsTT	c.68-5_68-3delCTCinsTT	c.68-5_68-3delCTCinsTT	rs397516362
deletion	c.562_563delCA	-	c.562_563delCA	c.562_563delCA	c.564delGinsCAG	PTV003
insertion		c.2339_2340insGGGCTCCCC	c.2331_2339dupGGGCTCCCC	c.2331_2339dupGGGCTCCCC		COSM12555 *

Protein HGVS

effect	ClinVar	COSMIC	SnpEff	Vep	VR	Reference ID
synonymous variant	p.Arg317=	-	p.Arg317Arg	p.=	p.Arg317=	rs111033272
synonymous variant	-	p.*1143*	p.Ter1143Ter	p.=	-	COSM3558732
stop gained	p.Gln100Ter	-	p.Gln100*	p.Gln100Ter	-	rs119103276
extension variant	-	p.*1133L	p.Ter1133Leuext*?	p.Ter1133LeuextTer22	-	COSM1569676
inframe insertion	-	-	p.Arg309_Arg310insArgArg	p.Arg310_Arg311dup	p.Arg311_Lys312insArgArg	PTV111
inframe insertion	-	p.T502_His505delTTGH	p.Thr502_His505del	p.Thr502_His505del	-	COSM1163654
inframe deletion	-	-	p.Ala1111_Ala1119del	p.Ala1111_Ala1119del	p.Ala1119_Gly1120insAlaAlaAlaAlaAlaAlaAlaAlaAla	PTV021
inframe deletion	-	p.N442delN	p.Asn442del	p.Asn442del	-	COSM5074446
frameshift variant	p.Arg227Lysfs	-	p.Arg227fs	p.Arg227LysfsTer31	-	rs80356649
frameshift variant	-	p.P1176fs*>46	p.Pro1176fs	p.Pro1176AlafsTer117	-	COSM5196763
frameshift variant	-	p.R613fs*15	p.Arg613fs	p.Arg613AlafsTer15	-	COSM5193613
frameshift variant	-	-	p.Glu238fs	p.Glu238ProfsTer9	p.Phe237_Glu238insPro	PTV008
inframe insertion	-	p.Pro780_Tyr781insGlySerPro	p.Pro780_Tyr781insGlySerPro	p.Gly778_Pro780dup	-	COSM12555 *

* known in My Cancer Genome as "c.2339_2340ins (G778_P780dup)"